UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2023.
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its charter)
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | ☒ | Form 40-F |
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
ADC Therapeutics SA (the “Company”) provided to its shareholders an invitation to the Company’s annual general meeting. The annual general meeting is expected to take place on June 14, 2023 at 4:00 a.m. EDT / 10:00 a.m. CEST at the Company’s headquarters at Biopôle, Route de la Corniche 3B, 1066, Epalinges, Switzerland.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ADC Therapeutics SA | ||
| Date: May 5, 2023 | ||
| By: | /s/ Peter J. Graham | |
| Name: | Peter J. Graham | |
| Title: | Chief Legal Officer | |
EXHIBIT INDEX
| Exhibit No. | Description |
| 99.1 | Invitation to the Annual General Meeting |
| 99.2 | ADC Therapeutics SA Shareholder Meeting Notice |
| 99.3 | Annual General Meeting Proxy Card (Record Holders) |
| 99.4 | Annual General Meeting Proxy Card (Brokers) |
